{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:50:24Z","timestamp":1794466224757,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"DOI":"10.1038\/s43587-026-01084-4","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:02:55Z","timestamp":1771581775000},"page":"626-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson\u2019s disease"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-3716","authenticated-orcid":false,"given":"M. H.","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2819-6029","authenticated-orcid":false,"given":"A.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Klint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pellecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-6921","authenticated-orcid":false,"given":"K.","family":"Kieburtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bellaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Klos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-1203","authenticated-orcid":false,"given":"R. A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-6779","authenticated-orcid":false,"given":"K.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3826-6694","authenticated-orcid":false,"given":"A.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"LeDoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Shpiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3816-4783","authenticated-orcid":false,"given":"P.","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7906-0388","authenticated-orcid":false,"given":"M.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Purino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mantri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9565-169X","authenticated-orcid":false,"given":"S.","family":"Parashos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Justiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Robottom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blindauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bellows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Goudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/mds.23878","volume":"26","author":"JP Bach","year":"2011","unstructured":"Bach, J. P. et al. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov. Disord. 26, 2286\u20132290 (2011).","journal-title":"Mov. Disord."},{"key":"1084_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/pharmrev.120.000189","volume":"73","author":"SK Pirooznia","year":"2021","unstructured":"Pirooznia, S. K. et al. Parkinson disease: translating insights from molecular mechanisms to neuroprotection. Pharmacol Rev. 73, 33\u201397 (2021).","journal-title":"Pharmacol Rev."},{"key":"1084_CR3","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1172\/JCI29178","volume":"116","author":"JM Savitt","year":"2006","unstructured":"Savitt, J. M. et al. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116, 1744\u20131754 (2006).","journal-title":"J. Clin. Invest."},{"key":"1084_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mds.23795","volume":"27","author":"KA Jellinger","year":"2019","unstructured":"Jellinger, K. A. Neuropathology of sporadic PD: evaluation and changes of concepts. Mov. Disord. 27, 8\u201330 (2019).","journal-title":"Mov. Disord."},{"key":"1084_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.28858","volume":"37","author":"MH Werner","year":"2022","unstructured":"Werner, M. H. & Olanow, C. W. PD modification through Abl kinase inhibition: an opportunity. Mov. Disord. 37, 6\u201315 (2022).","journal-title":"Mov. Disord."},{"key":"1084_CR6","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/nn.3500","volume":"16","author":"Y Lee","year":"2013","unstructured":"Lee, Y. et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat. Neurosci. 16, 1392\u20131400 (2013).","journal-title":"Nat. Neurosci."},{"key":"1084_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba1659","volume":"11","author":"VL Dawson","year":"2019","unstructured":"Dawson, V. L. & Dawson, T. M. Promising disease-modifying therapies for PD. Sci. Transl. Med. 11, eaba1659 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1084_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abp9352","volume":"15","author":"S Karuppagounder","year":"2023","unstructured":"Karuppagounder, S. et al. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic PD. Sci. Transl. Med. 15, eabp9352 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1084_CR9","doi-asserted-by":"publisher","first-page":"105184","DOI":"10.1016\/j.nbd.2020.105184","volume":"148","author":"DJ Marmion","year":"2021","unstructured":"Marmion, D. J. et al. Viral-based rodent and nonhuman primate models of multiple system atrophy: fidelity to the human disesae. Neurobiol. Dis. 148, 105184 (2021).","journal-title":"Neurobiol. Dis."},{"key":"1084_CR10","doi-asserted-by":"crossref","first-page":"abstr. 155","DOI":"10.1002\/mds.29250","volume":"38","author":"M Werner","year":"2023","unstructured":"Werner, M. et al. Analysis of the therapeutic potential of c-Abl inhibition in multiple system atrophy. Mov. Disord. 38, abstr. 155 (2023).","journal-title":"Mov. Disord."},{"key":"1084_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/JPD-230319","volume":"14","author":"MH Werner","year":"2024","unstructured":"Werner, M. H. et al. A phase I, randomized, SAD, MAD, and PK study of risvodetinib in older adults and PD. J. Parkinsons Dis. 14, 325\u2013334 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1084_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3988\/jcn.2019.15.2.135","volume":"15","author":"JY Kim","year":"2019","unstructured":"Kim, J. Y. et al. \u03b1-Synuclein in skin nerve fibers as a biomarker for \u03b1-synucleinopathies. J. Clin. Neurol. 15, 135\u2013142 (2019).","journal-title":"J. Clin. Neurol."},{"key":"1084_CR13","doi-asserted-by":"publisher","first-page":"e1529","DOI":"10.1212\/WNL.0000000000206772","volume":"100","author":"C Gibbons","year":"2023","unstructured":"Gibbons, C. et al. Cutaneous \u03b1-synuclein signatures in patients with multiple system atrophy and Parkinson disease. Neurology 100, e1529\u2013e1539 (2023).","journal-title":"Neurology"},{"key":"1084_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons, C. H. et al. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA 331, 1298\u20131306 (2024).","journal-title":"JAMA"},{"key":"1084_CR15","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1172\/JCI85456","volume":"126","author":"S Brahmachari","year":"2016","unstructured":"Brahmachari, S. et al. Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration. J. Clin. Invest. 126, 2970\u20132988 (2016).","journal-title":"J. Clin. Invest."},{"key":"1084_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","volume":"31","author":"SZ Imam","year":"2011","unstructured":"Imam, S. Z. et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for PD. J. Neurosci. 31, 157\u2013163 (2011).","journal-title":"J. Neurosci."},{"key":"1084_CR17","doi-asserted-by":"publisher","first-page":"16691","DOI":"10.1073\/pnas.1006083107","volume":"107","author":"HS Ko","year":"2010","unstructured":"Ko, H. S. et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin\u2019s ubiquitination and protective function. Proc. Natl Acad. Sci. USA 107, 16691\u201316696 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1084_CR18","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/brain\/awz172","volume":"142","author":"S Brahmachari","year":"2019","unstructured":"Brahmachari, S. et al. Parkin interacting substrate zinc finger protein 746 is a pathological mediator in PD. Brain 142, 2380\u20132401 (2019).","journal-title":"Brain"},{"key":"1084_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in non-transgenic mice. Science 338, 949\u2013953 (2012).","journal-title":"Science"},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","volume":"144","author":"JH Shin","year":"2011","unstructured":"Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1\u03b1 contributes to neurodegeneration in PD. Cell 144, 689\u2013702 (2011).","journal-title":"Cell"},{"key":"1084_CR21","doi-asserted-by":"publisher","first-page":"49071","DOI":"10.1074\/jbc.M208046200","volume":"277","author":"M Hasegawa","year":"2002","unstructured":"Hasegawa, M. et al. Phosphorylated \u03b1-synuclein is ubiquitinated in \u03b1-synucleinopathy lesions. J. Biol. Chem. 277, 49071\u201349076 (2002).","journal-title":"J. Biol. Chem."},{"key":"1084_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160\u2013164 (2002).","journal-title":"Nat. Cell Biol."},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","volume":"23","author":"AL Mahul-Mellier","year":"2014","unstructured":"Mahul-Mellier, A. L. et al. c-Abl phosphorylates \u03b1-synuclein and regulates its degradation: implication for \u03b1-synuclein clearance and contribution to the pathogenesis of PD. Hum. Mol. Genet. 23, 2858\u20132879 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1084_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MWN Deininger","year":"2003","unstructured":"Deininger, M. W. N. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21, 1637\u20131647 (2003).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder, S., Sharma, U. C. & Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct. Target. Ther. 8, 262 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1084_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","volume":"79","author":"GK Tofaris","year":"2022","unstructured":"Tofaris, G. K. Initiation and progression of \u03b1-synuclein pathology in PD. Cell. Mol. Life Sci. 79, 210 (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"1084_CR27","unstructured":"Konnova E. A. and Swanberg M. in Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects (eds Stoker, T. B. & Greenland, J. C.) (Codon Publications, 2018)."},{"key":"1084_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2024","unstructured":"Vijiaratnam, N. et al. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20, 559\u2013572 (2024).","journal-title":"Lancet Neurol."},{"key":"1084_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya, H. et al. Discrepancy between distribution of \u03b1-synuclein oligomers and Lewy-related pathology in PD. Acta Neuropathol. Commun. 10, 133 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2013","unstructured":"Goedert, M. et al. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13\u201324 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"1084_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga, S. et al. Neuropathology and molecular diagnosis of synucleinopathies. Mol. Neurodeg. 16, 83 (2021).","journal-title":"Mol. Neurodeg."},{"key":"1084_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104587","volume":"132","author":"D Chatterjee","year":"2019","unstructured":"Chatterjee, D. et al. Immunotherapy in PD: Current status and future directions. Neurobiol. Dis. 132, 104587 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1084_CR33","doi-asserted-by":"publisher","first-page":"104760","DOI":"10.1016\/j.nbd.2020.104760","volume":"137","author":"AD Schwab","year":"2019","unstructured":"Schwab, A. D. et al. Immunotherapy for PD. Neurobiol. Dis. 137, 104760 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1084_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41531-023-00552-7","volume":"9","author":"DL Price","year":"2023","unstructured":"Price, D. L. et al. In vivo effects of the \u03b1-synuclein misfolding inhibitor minzasolmin supports clinical development in PD. npj Parkinson\u2019s Dis. 9, 114 (2023).","journal-title":"npj Parkinson\u2019s Dis."},{"key":"1084_CR35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and PD. Acta Neuropathol. 125, 795\u2013813 (2013).","journal-title":"Acta Neuropathol."},{"key":"1084_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2019","unstructured":"Heras-Garvin, A. et al. Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov. Disord. 34, 255\u2013263 (2019).","journal-title":"Mov. Disord."},{"key":"1084_CR37","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing, K. et al. PD drug therapies in the clinical trial pipeline: 2024 update. J. Parkinson\u2019s Dis. 14, 899\u2013912 (2024).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"1084_CR38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba, J. K. et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Del. Rev. 54, 1271\u20131294 (2002).","journal-title":"Adv. Drug Del. Rev."},{"key":"1084_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","volume":"37","author":"M von Mehren","year":"2010","unstructured":"von Mehren, M. et al. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?. Cancer Treat. Rev. 37, 291\u2013299 (2010).","journal-title":"Cancer Treat. Rev."},{"key":"1084_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan, F. L. et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 77, 309\u2013317 (2020).","journal-title":"JAMA Neurol."},{"key":"1084_CR41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/mds.28389","volume":"36","author":"FL Pagan","year":"2021","unstructured":"Pagan, F. L. et al. Long-term safety and clinical effects of nilotinib in PD. Mov. Disord. 36, 740\u2013749 (2021).","journal-title":"Mov. Disord."},{"key":"1084_CR42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","volume":"78","author":"T Simuni","year":"2021","unstructured":"Simuni, T. et al. Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial. JAMA Neurol. 78, 312\u2013320 (2021).","journal-title":"JAMA Neurol."},{"key":"1084_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.470","volume":"7","author":"FL Pagan","year":"2019","unstructured":"Pagan, F. L. et al. Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with PD. Pharmacol. Res. Perspect. 7, e00470 (2019).","journal-title":"Pharmacol. Res. Perspect."},{"key":"1084_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","volume":"77","author":"O Antelope","year":"2019","unstructured":"Antelope, O. et al. BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp. Hematol. 77, 36\u201340.e2 (2019).","journal-title":"Exp. Hematol."},{"key":"1084_CR45","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1182\/blood-2019-129751","volume":"134","author":"JE Cortes","year":"2019","unstructured":"Cortes, J. E. et al. Phase 1 trial of K0706, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): in patients with chronic myelogenous leukemia (CML) and Phildelphia positive acute lymphoblastic leukemia (Ph+ ALL) failing \u2265 3 prior TKI therapies: initial safety and efficacy. Blood 134, 4158 (2019).","journal-title":"Blood"},{"key":"1084_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P2.8-047","volume":"92","author":"A Goldfine","year":"2019","unstructured":"Goldfine, A. et al. Results of a phase 1 dose-ranging trial, and design of a phase 2 trial, of K0706, a novel c-Abl tyrosine kinase inhibitor for PD. Neurology 92, P2.8-047 (2019).","journal-title":"Neurology"},{"key":"1084_CR47","unstructured":"Sun Pharma Advanced Research Company. 2014\u20132024 Disclosures. https:\/\/sparc.life\/presentations"},{"key":"1084_CR48","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","volume":"27","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. The c-Abl inhibitor, radotinib HCl, is neuroprotective in a preclinical PD mouse model. Hum. Mol. Genet. 27, 2344\u20132356 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"1084_CR49","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/cam4.1436","volume":"7","author":"H Noh","year":"2018","unstructured":"Noh, H. et al. Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. Cancer Med. 7, 1766\u20131773 (2018).","journal-title":"Cancer Med."}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01084-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01084-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01084-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:01:49Z","timestamp":1774029709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01084-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1038\/s43587-026-01084-4","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.W. is the Founder, was Chief Executive and remains a shareholder of Inhibikase Therapeutics, and is the Founder and a shareholder of ABLi Therapeutics. C.M., C.K. and J.P. are, or were, employees and shareholders of Inhibikase Therapeutics, and C.M. is a shareholder of ABLi Therapeutics. C.W.O is the past Chief Executive of Clintrex Research and K. Kieburtz is the current Managing Director of Clintrex. Clintrex Research provides services to many pharmaceutical and biotech companies, including Inhibikase and ABLi. C.W.O. was a shareholder of Inhibikase and served as an expert witness in the paraquat litigation. T.L. is Chief Medical Officer and shareholder of CND Life Sciences. R.F. is a shareholder of CND Life Sciences and Inhibikase Therapeutics, and was a board member of Inhibikase. C.G. is the Chief Scientific Officer of CND Life Sciences and is a shareholder. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}